Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Summary
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Summary
Loss from operations decreased 22% to $3.6 million.The following is a summary of the Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript:
以下是apyx medical公司（APYX）2024年第三季度業績會議電話記錄摘要：
Financial Performance:
財務表現：
Reported a total quarterly revenue of $11.5 million, a decrease of 4% year-over-year.
Gross profit for the quarter decreased 13% to $7 million with a margin of 60.5%, compared to 66.6% in the prior year.
Loss from operations decreased 22% to $3.6 million.
Net loss for shareholders increased slightly to $4.7 million or $0.14 per share.
Revised full year guidance anticipates a decrease in total revenue by approximately 11% to 9% year-over-year to $46.6 million to $47.6 million.
報告了總季度營業收入1150萬美元，同比下降4%。
季度毛利潤下降13%，至700萬美元，利潤率爲60.5%，而去年同期爲66.6%。
經營虧損減少22%，至360萬美元。
股東淨虧損略有增加，達到470萬美元，每股0.14美元。
修訂的全年指導意見預計，總營收將同比下降約11%至9%，至4660萬至4760萬美元。
Business Progress:
業務進展：
Undergoing a strategic restructuring including a reduction of the U.S. workforce by 25%.
Introduction of the Ayon body contouring system; planning to submit a 510(k) to the FDA, expected to launch in the second half of 2025.
Announced promotion of Shawn Roman to Chief Operating Officer.
Expanding direct-to-consumer campaigns and initiatives to educate both physicians and patients on Renuvion technology.
正在進行戰略重組，包括將美國員工數量減少25%。
推出Ayon塑身系統；計劃向FDA提交510(k)申請，預計將於2025年下半年推出。
宣佈將Shawn Roman晉升爲首席運營官。
擴大面向消費者的直接推廣活動和倡議，以教育醫師和患者關於Renuvion技術。
Opportunities:
機會：
Projected increase in demand for Renuvion technology due to the side effects of GLP-1 drugs, leading to a growing market for surgical treatments of loose skin.
Anticipation of capturing new market shares and expanding the total addressable market in aesthetic surgery with the upcoming launch of the Ayon body contouring system.
預計由於GLP-1藥物的副作用而導致對Renuvion技術需求增加，從而推動鬆弛皮膚手術治療市場的增長。
期待通過即將推出的Ayon塑身系統捕獲新的市場份額，並拓展美學手術領域的總體市場規模。
Risks:
風險：
Continued soft performance in generator capital sales attributed to macroeconomic pressures and competition from non-invasive aesthetic procedures.
Potential near term impacts on capital equipment sales as customers may postpone purchases in anticipation of the new Ayon system.
Dependency on the successful review and approval by the FDA of the new Ayon system, and effective integration of numerous surgical technologies.
發電機資本銷售的低表現歸因於宏觀經濟壓力和來自非侵入性美容程序的競爭。
由於客戶可能推遲購買以期待新的Ayon系統，可能對資本設備銷售產生潛在的近期影響。
依賴於FDA對新Ayon系統的成功審查和批准，以及對多種外科技術的有效整合。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情，請參閱IR網站。本文僅供投資者參考，不具有任何指導或推薦建議。
